Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

Experimental Neurology

Volumn 151, Issue 2, 1998, Pages 334-342

  Henry, Brian ^a   Crossman, Alan R ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

6 Hydroxydopamine; L DOPA induced dyskinasia; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; LEVODOPA; LISURIDE; MAZINDOL; OXIDOPAMINE; PROPRANOLOL; YOHIMBAN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; CIRCLING BEHAVIOR; CONTROLLED STUDY; DYSKINESIA; HYPERKINESIA; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0032103897     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6819     Document Type: Article

References (40)

1. Ahlskog J. E., Wright K. F., Muenter M. D., Adler C. H. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect. Clin. Neuropharmacol. 19:1996;202-212.
2. Barbeau A. The clinical physiology of side effects in long-term L-dopa therapy. Adv. Neurol. 5:1974;347-365.
3. 3. Brain Res. 379:1986;294-299.
4. Bedard P. J., Mancilla B. G., Blanchett P., Gagnon C., Di Paolo T. Levodopa-induced dyskinesia: Facts and fancy. What dose the MPTP monkey model tell us. Can. J. Neurol. Sci. 19:1992;134-137.
5. Bevan P. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity. Neurosci. Lett. 25:1983;185-189.
6. Blanchet P. J., Gomez-Mancilla B., Bedard P. J. DOPA-induced 'peak-dose' dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J. Neural. Transm. (Supp). 45:1995;103-112.
7. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
8. Calne D. B., Plotkin C., Williams A. C., Nutt J. G., Neophytides A., Teychenne P. F. Long-term treatment of parkinsonism with bromocriptine. Lancet. 1:1978;735-738.
9. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in parkinsonism. Br. Med. J. 4:1974;442-444.
10. Carey R. J. Naloxone reverses L-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci. 48:1991;1303-1308.
11. Carpentier A. F., Bonnet A. M., Vidailhet M., Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology. 46:1996;1548-1551.
12. Clarke C. E., Sambrook M. A., Mitchell I. J., Cross man A. R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 79:1987;273-280.
13. Cooper D. R., Marrel C., Testa B., van de Waterbeemd H., Quinn N., Jenner P., Marsden C. D. L-Dopa methyl ester: A candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin. Neuropharmacol. 7:1984;89-98.
14. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of parkinsonism: Chronic treatment with L-dopa. N. Engl. J. Med. 280:1969;337-345.
15. Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology. 45:1995;1855-1858.
16. Duty S., Brotchie J. M. Enhancement of behavioural response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
17. Gomez-Mancilla B., Bedard P. J. Effect of nondopaminergic drugs onL. Clin. Neuropharm. 16:1993;418-427.
18. Graham W. C., Crossman A. R., Woodruff G. N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res. 514:1990;93-102.
19. Henry B., Brotchie J. M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;149-158.
20. 2. Soc. Neurosci. Abstract (USA). 21:1997;560.3.
21. Hoehn M. M. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease. Acta. Neurol. Scand. 71:1985;97-106.
22. 3. J. Neurosci. 5:1985;1513-1521.
23. Kartzinel R., Teychenne P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., Calne D. B. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 2:1976;272-275.
24. Lees A. J., Stern G. M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 44:1981;1020-1023.
25. Lees A. J. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br. Med. J. 307:1993;469-472.
26. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of Parkinson's disease with bromocriptine. N. Eng. J. Med. 295:1976;1400-1404.
27. Molho E. S., Factor S. A., Weiner W. J., Sanchez-Ramos J. R., Singer C., Shulman L., Brown D., Sheldon C. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J. Neural. Transm. Suppl. 45:1995;225-230.
28. Nutt J. G. Levodopa-induced dyskinesia. Neurology. 40:1990;340-345.
29. Parkes J. D., Debono A. G., Marsden C. D. Bromocriptine in parkinsonism: long-term treatment dose response, and comparison with levodopa. J. Neurol. Neurosurg. Psychiatry. 39:1976;1101-1108.
30. Paxinos G., Watson C. The Rat Brain in Stereotatic Coordinates. 1986;Academic Press, San Diego.
31. Pearce R. K., Jackson M., Smith L., Jenner P., Marsden C. D. ChronicLCallithrix Jacchus. Mov. Dis. 10:1995;731-740.
32. 2. Mov. Dis. 12:1997;111.
33. Rascol O., Lees A. J., Senard J. M., Pirtosek Z., Montastruc J. L., Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin. Neuropharmacol. 19:1996;234-245.
34. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up. Neurology. 37:1987;826-828.
35. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 39:1989;336-339.
36. Tolosa E. S., Martin W. E., Cohen H. P. Dyskinesias during levodopa therapy. Lancet. 1:1975;1381-1382.
37. Trugman J. M., Wooten G. F. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilisation in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J. Neurosci. 7:1987;2927-2935.
38. Ungerstedt U., Arbuthnott G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
39. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta. Physiol. Scand. Suppl. 367:1971;69-93.
40. Yahr M. D., Duvosin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch. Neurol. 21:1969;343-354.